2-[(1E)-2-(3,5-Dihydroxyphenyl)ethenyl]-1,3-benzenediol

Male Sprague-Dawley rats were cannulated and dosed either intravenously with Gnetol (10?μg/kg) or orally (100?mg/kg). After oral and intravenous administration, Gnetol is detected in both serum and urine as the parent compound and as a glucuronidated metabolite. The bioavailability of Gnetol is determined to be 6%. Gnetol is rapidly glucuronidated and is excreted in urine and via nonrenal routes^[1].
Pretreatment of Male NIH Swiss mice (20-35 g) with Gnetol (50mg/kg, SC) is able to increase the latency period to response in analgesia models^[1].